Biomarker Analysis and the Implications for the Treatment of Non-Small Cell Lung Cancer


BiomarkersLung17

Interview with Gregory J Riely, MD, PhD

Track 1: Classification of metastatic non-small cell lung cancer (NSCLC) based on biomarker analysis
Track 2: Optimal testing platforms for patients with metastatic NSCLC
Track 3: Molecular profiling to detect targetable alterations in patients with newly diagnosed metastatic nonsquamous NSCLC
Track 4: Choice of first-line therapy for patients with metastatic squamous NSCLC and no targetable mutations
Track 5: Ongoing investigation of immune checkpoint inhibitors with chemotherapy as first-line treatment for metastatic squamous NSCLC with no targetable mutation
Track 6: Duration and level of response to immune checkpoint inhibitors based on PD-L1 tumor proportion score (TPS)
Track 7: Use of immune checkpoint inhibitors in combination with chemotherapy as front-line therapy for metastatic nonsquamous NSCLC without a targetable mutation
Track 8: Selection of EGFR tyrosine kinase inhibitors (TKIs) as first-line therapy for EGFR-mutated NSCLC
Track 9: Types of EGFR mutations and activity of EGFR TKIs
Track 10: Efficacy and tolerability of the EGFR TKI osimertinib as first-line therapy
Track 11: Mechanisms of acquired resistance to osimertinib
Track 12: Response to EGFR TKIs in patients with CNS metastases
Track 13: Plasma versus tissue genotyping for detection of T790M mutations
Track 14: Response to osimertinib in patients with T790M-negative metastatic NSCLC
Track 15: Therapeutic options for patients with T790M-negative metastatic NSCLC
Track 16: Choosing between targeted therapy and immunotherapy for patients with metastatic nonsquamous NSCLC and actionable mutations
Track 17: Management of lung cancer in patients with ALK and ROS1 genomic alterations
Track 18: Selection of up-front therapy for BRAF mutation-positive metastatic NSCLC
Track 19: MET exon 14 alterations and implications for treatment
Track 20: Sequencing therapy for patients with RET rearrangements
Track 21: Efficacy of HER2-targeted therapy for patients with metastatic NSCLC and HER2 alterations
Track 22: Analysis of PD-L1 expression and variation over time

Interview with Marc Ladanyi, MD

Track 1: Molecular pathology of lung cancer
Track 2: Genomic testing for patients with newly diagnosed metastatic NSCLC
Track 3: Actionable alterations in patients with adenocarcinoma of the lung
Track 4: Targeting KRAS mutation-positive NSCLC
Track 5: Assays to detect genomic alterations in patients with lung cancer
Track 6: Biology of MET exon 14 alterations in NSCLC
Track 7: Incidence of RET fusions in patients with lung adenocarcinoma; response to targeted therapy
Track 8: Activity of NTRK inhibitors in patients with NTRK fusions
Track 9: MSK-IMPACTTM: Next-generation sequencing assay to detect genomic alterations and inform therapeutic decision-making
Track 10: Mechanisms of resistance to EGFR TKIs
Track 11: T790M mutation testing for patients who develop resistance to EGFR TKIs
Track 12: Acquired EGFR C797S mutation as a mechanism of resistance to osimertinib
Track 13: Detection of ALK fusions in NSCLC
 
FACULTY
 
Gregory J Riely, MD, PhD
Associate Attending
Memorial Sloan Kettering
Cancer Center
New York, New York

 

Marc Ladanyi, MD
Molecular Geneticist
Chief, Molecular
Diagnostics Service
William J Ruane
Chair in Molecular Oncology
Memorial Sloan Kettering
Cancer Center
New York, New York
 
EDITOR
 
Neil Love, MD
Research To Practice
Miami, Florida